Molecular Pathology and Molecular Pharmacology of Osteosarcoma
- 1 January 2000
- journal article
- Published by Taylor & Francis in Pediatric Pathology & Molecular Medicine
- Vol. 19 (5), 391-413
- https://doi.org/10.1080/15513810009168647
Abstract
No abstract availableThis publication has 99 references indexed in Scilit:
- Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcomaJournal of Surgical Oncology, 1998
- Role of the Rb/E2F pathway in cell growth controlJournal of Cellular Physiology, 1997
- Transcript Mapping in a 46-kb Sequenced Region at the Core of 12q13.3 Amplification in Human CancersGenomics, 1997
- Alterations of thep53, Rb andMDM2 genes in osteosarcomsZeitschrift für Krebsforschung und Klinische Onkologie, 1996
- Biology of the multidrug resistance-associated protein, MRPEuropean Journal Of Cancer, 1996
- MDR1 gene expression: Evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomasEuropean Journal Of Cancer, 1996
- p53 Status and the Efficacy of Cancer Therapy in VivoScience, 1994
- Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53Nature, 1993
- Prognostic significance of bone morphogenetic activity in osteosarcoma tissueCancer, 1988
- Amplification and organization of dihydrofolate reductase genes in a human leukemic cell line, K-562, resistant to methotrexateBiochemistry, 1983